NBC11.com - Local News (Free subscription) | yesterday
San Francisco Mayor Gavin Newsom has announced that Pfizer Inc. will relocate its biotech research center to the city, a move leaders hope will attract other biomedical businesses.
San Fransisco Chronicle (Free subscription) | yesterday
San Francisco Mayor Gavin Newsom has announced that Pfizer Inc. will relocate its biotech research center to the city, a move leaders hope will attract other biomedical businesses. Newsom says the company plans to move the unit in early 2010 from its current...
Business Wire (Free subscription) | yesterday
NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that, in patients with heart disease, type 2 diabetes and chronic kidney disease, Lipitor
San Fransisco Chronicle (Free subscription) | yesterday
San Francisco's drive to become a major hub of the biotechnology industry got a big boost Tuesday when Pfizer Inc., the world's largest drugmaker, said it will move the headquarters of its new biotech research unit to Mission Bay, next door to UCSF's new...
San Fransisco Chronicle (Free subscription) | yesterday
San Francisco's drive to become a major hub of the biotechnology industry got a big boost today when Pfizer Inc., the world's largest drugmaker, said it will move the headquarters of its new biotech research unit to Mission Bay, next door to UCSF's new...
WorkAtHome (Free subscription) | 08/05/2008
Alexandria Real Estate Equities, Inc. , Landlord of Choice to the Life Science Industry®, today announced that Pfizer Inc. has entered into a long-term lease for approximately 100,000 square feet, with an option for an additional 50,000 square feet, at 455 Mission Bay Boulevard South, San Francisco, California.
The San Francisco Business Times (Free subscription) | 08/05/2008
Pfizer Inc., the world's largest drugmaker, is coming to San Francisco's Mission Bay.
The Age (Free subscription) | 08/04/2008
Athletes competing at the Beijing Olympics are already canvassing the latest ways to cheat.
Business Wire (Free subscription) | 08/04/2008
CHICAGO--(BUSINESS WIRE)--Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting
atHome Top Story (Free subscription) | 08/01/2008
The big pharma folks who brought us Viagra would really pump up their sales if only they could find a way to market it to women.
Red Orbit (Free subscription) | 08/01/2008
HAMBURG, Germany, Aug. 1, 2008 (PRIME NEWSWIRE) -- Evotec AG (Nasdaq:EVTC) (Frankfurt:EVT) announced today that dose escalation studies for a Phase I clinical trial of a small molecule VR1 (vanilloid receptor 1) antagonist is being progressed by Pfizer Inc. under the collaboration with Evotec.
Medical News Today (Free subscription) | 07/31/2008
Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that its partner, Pfizer Inc, initiated patient dosing in a Phase II trial evaluating PF-4523655 (RTP801i-14) in patients with diabetic macular edema (DME).
Medical News Today (Free subscription) | 07/31/2008
Eisai Inc. and Pfizer Inc (NYSE: PFE) announced results from a new open-label study that showed Hispanics with mild to moderate Alzheimer's disease (AD) experienced significant improvement in cognition compared to baseline after 12 weeks of treatment with ARICEPT.
The East Bay Business Times (Free subscription) | 07/30/2008
Quark Pharmaceuticals Inc. and Pfizer Inc. began dosing patients in a Phase II trial of their RNA interference treatment for diabetic macular edema, triggering a milestone payment from Pfizer. (PFE)
The San Francisco Business Times (Free subscription) | 07/30/2008
Quark Pharmaceuticals Inc. and Pfizer Inc. started dosing patients in a Phase II trial of their RNA interference treatment for diabetic macular edema, triggering a milestone payment from Pfizer. (PFE)
